close

You are going to a website that contains clinical information and was created specifically for healthcare professionals. If you are not a healthcare professional, and would like to return to the consumer site, please click the RETURN link below.

⇐ RETURN TO PREVIOUS PAGE
Continue
To the healthcare professional site

Thymogam as Induction Therapy In Prevention of Rejection

The goal of induction therapy is to prevent acute rejection during the early post transplantation period by providing a high degree of immunosuppression at the time of transplantation. Induction therapy is often considered essential to optimize outcomes, particularly in patients at high risk for poor short-term outcomes.

All of the induction immunosuppressive agents currently used are biological agents and are either monoclonal (muromonab-CD3, daclizumab, basiliximab, alemtuzumab) or polyclonal (antithymocyte globulin [equine]/Thymogam or antithymocyte globulin [rabbit]) antibodies.

Thymogam at a single bolus dose of 25mg/kg one day before transplant helps to prevent acute rejection in Renal Transplant.

T
P
T